Company news

Immutep Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immutep secures commitments for A$60 million in a Placement

June 20, 2021

Immutep global webcast slides

June 9, 2021

Immutep Reveals a New anti-LAG-3 Research Program

June 7, 2021

Immutep Reports Positive Data from its TACTI-002 ph 2 trial

June 4, 2021

Immutep granted European patent for its LAG-3 candidate Efti

June 2, 2021

Immutep enters New Collaboration with Merck KGaA for Efti

May 31, 2021

Immutep granted Chinese patent for its LAG-3 candidate Efti

May 26, 2021

Operational Update

May 7, 2021

TACTI-002 & INSIGHT-004 data to be presented at ASCO

April 28, 2021

Immutep receives A$1,155,055 R&D Tax Incentive

April 16, 2021

Immutep achieves Fast Track designation for Efti from US FDA

April 7, 2021

Immutep announces European Patent Grant for LAG525

April 6, 2021

Immutep collaborates with MSD for phase 2b head & neck trial

March 15, 2021

S&P DJI Announces March 2021 Quarterly Rebalance

March 12, 2021

Immutep secures second US patent grant for eftilagimod alpha

March 9, 2021

Phase II study for eftilagimod alpha in COVID-19 advances

January 26, 2021

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

January 21, 2021

Recruitment of head & neck cancer patients completed for ph2

January 6, 2021

Immutep granted US patent for eftilagimod alpha with a PD-1

December 29, 2020

Immutep Upscales Efti Manufacturing

December 16, 2020

Immuteps partner EOC pharma to start Ph II trial in MBC

December 9, 2020

Proposed issue of Securities - IMM

November 18, 2020

Pause in Trading

November 17, 2020

Encouraging Phase II TACTI-002 data reported at SITC 2020

November 9, 2020

Immutep Announces Australian Patent Grant for IMP701

November 8, 2020

Immutep enters into a Licence & Collaboration with LabCorp

October 29, 2020

2020 AGM Presentation

October 26, 2020

COVID-19 phase 2 investigator initiated trial commences

October 22, 2020

Immutep granted European patent for IMP761

October 21, 2020

Immutep reports improving results from INSIGHT-004 trial

September 17, 2020

IMM & Monash Uni receive funding grant for LAG-3 Research

August 30, 2020

Appendix 4E & 2020 Full Year Statutory Accounts

August 25, 2020

Recruitment of stage 1 of part B in TACTI-002 study complete

August 17, 2020

Immutep granted US patent for eftilagimod alpha

August 11, 2020

US patent granted for IMP701 antibody

July 14, 2020

Immutep Completes Recruitment for Part A of TACTI-002 trial

June 28, 2020

Immutep receives A$1,437,826 R&D Tax Incentive

June 21, 2020

Immutep announces improving data from TACTI-002 ph II trial

May 31, 2020

Immutep receives $3.6M R&D French tax incentive

May 28, 2020

Immutep granted Japanese patent for eftilagimod alpha

May 6, 2020

INSIGHT-004 and TACTI-002 data to be presented at ASCO

April 29, 2020

Immutep Investor Presentation

April 28, 2020

Immutep Reports Positive Phase II TACTI-002 Data

April 27, 2020

Enrollment completed for the INSIGHT-004 Study

April 21, 2020

Immutep March Quarterly Activities Report & Appendix 4C

April 20, 2020

Immutep advances its LAG-3 agonist for autoimmune diseases

April 15, 2020

Immutep presents TACTI-002 data at AACR Virtual Meeting

April 14, 2020

EOC Pharma confirms plans to advance Efti in China for MBC

April 8, 2020

Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides

March 25, 2020

Immutep reports supportive efficacy data from AIPAC study

March 24, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 112 decks. Every deck is listed under its year.